Inhibition of autophagy increases proliferation inhibition and apoptosis induced by the PI3K/mTOR inhibitor NVP-BEZ235 in breast cancer cells

Clinical Laboratory

Volumn 61, Issue 8, 2015, Pages 1043-1051

  Ji, Yinghua ^a   Di, Wenyu ^a   Yang, Qinghui ^a   Lu, Zhihong ^a   Cai, Weimei ^a   Wu, Jieqing ^a  

^a The Third Hospital of Xinxiang Medical University   (China)

Author keywords

Apoptosis; Autophagy; Breast cancer; MTOR; NVP BEZ235; PI3K

Indexed keywords

DACTOLISIB; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; 3-METHYLADENINE; ADENINE; ANTINEOPLASTIC AGENT; ATG7 PROTEIN, HUMAN; CHLOROQUINE; IMIDAZOLE DERIVATIVE; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE; S6 KINASE; TARGET OF RAPAMYCIN KINASE; UBIQUITIN PROTEIN LIGASE;

APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENETIC TRANSFECTION; GENETICS; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; TIME;

ADENINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AUTOPHAGY; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; CHLOROQUINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMIDAZOLES; MCF-7 CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLINES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRANSFECTION; UBIQUITIN-ACTIVATING ENZYMES;

EID: 84941637454     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2015.150144     Document Type: Article

References (26)

1. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379: 633-40.
2. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011;29:3366-73.
3. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
4. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001;17:615-75.
5. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 2002;5:234-48.
6. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signaling controls tumour cell growth. Nature 2006;441:424-30.
7. Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 2011;13:224.
8. Burris HA 3rd. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol 2013;71:829-42.
9. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 2011; 29:4452-61.
10. Hosford SR, Miller TW. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmacogenomics and Personalized Medicine 2014;7:203-15.
11. Zagour F, Sergentanis TN, Chrysikos D. mTOR inhibitors in breast cancer: A systematic review. Gynecologic Oncology 2012; 127:662-72.
12. Chen YL, Law PY, Loh HH. Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy. Curr Med Chem Anticancer Agents 2005;5:575-89.
13. Sawyers CL. Will mTOR inhibitors make it as cancer drugs? Cancer Cell 2003;4:343-8.
14. Bendell JC, Rodon J, Burris HA, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid rumors. J Clin Oncol 2012;30:282-90.
15. Xu C-X, Zhao L, Yue P, et al. Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy. Cancer Biology & Therapy 2011;12:549-55.
16. Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7:1851-63.
17. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008;132:27-42.
18. Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy 2007;3:542-5.
19. Klionsky DJ, Abeliovich H, Agostinis P, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008;4:151-75.
20. Ni HM, Bockus A, Wozniak AL, et al. Dissecting the dynamic turnover of GFP-LC3 in the autolysosome. Autophagy 2011;7: 188-204.
21. D.C. Rubinsztein, J.E. Gestwicki, L.O. Murphy, D.J. Klionsky, Potential therapeutic applications of autophagy. Nat Rev Drug Discov 2007;6:304-12.
22. Zhang H, Kong X, Kang J, et al. Oxidative stress induces parallel autophagy and mitochondria dysfunction in human glioma U251 cells. Toxicol Sci 2009;110:376-88.
23. Calvo-Garrido J, Carilla-Latorre S, Mesquita A, et al. A proteolytic cleavage assay to monitor autophagy in Dictyostelium discoideum. Autophagy 2011;7:1063-8.
24. Kim A, Park S, Lee JE, et al. The dual PI3K and mTOR inhibitor NVPBEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells. Leuk Res 2012;36:912-20.
25. Cavazzoni A, Bonelli MA, Fumarola C, et al. Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Lett 2012;323:77-87.
26. Su M, Mei Y, Sinha S. Role of the Crosstalk between Autophagy and Apoptosis in Cancer. Journal of Oncology 2013;2013:102735